NEW YORK (GenomeWeb News) – Genomatix Software said today that Pfizer has licensed use of its software and databases for use by Pfizer Pharmaceuticals’ sites around the world.
The Munich, Germany-based bioinformatics company said that Pfizer will use the software and data content “to help understand the molecular basis of how their potential drug targets may be co-regulated with other important targets, producing potential desirable or unwanted side effects.”
Financial terms of the license were not disclosed.